Seeking Alpha
24 Sept 2026, 17:49 UTC · 1h ago
Verdict
Headline takes no side. We score KYTX +1.00 across two claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Kyverna reported positive topline 1-year data from the KYSA-8 Registrational Trial of mivocabtagene autoleucel (Miv-cel) in Stiff-Person syndrome (SPS).
Newconference call dated September 24, 2026
So whatAs a registrational trial, positive 1-year data is a primary catalyst for a BLA filing within the next 12-18 months.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The company released topline longer-term follow-up data from the KYSA-6 Phase II trial in generalized myasthenia gravis (gMG).
Newconference call dated September 24, 2026
More positive than 86% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported positive topline data from its KYSA-8 registrational trial and longer-term follow-up data for its Phase II trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
−0.6%
Price is moving against the score
$7.03 vs $7.07 close before publication (Sep 23) · not market-adjusted
KYTX chart →
